SIMILAR EFFICACY AND DRUG SURVIVAL RATES OF BARICITINIB MONOTHERAPY AND BARICITINIB/METHOTREXATE COMBINATION THERAPY IN REAL-LIFE TREATMENT OF RHEUMATOID ARTHRITIS - RESULTS FROM A PROSPECTIVE COHORT OF BARICITINIB-TREATED PATIENTS

Bayat S, Tascilar K, Bohr D, Simon D, Kronke G, Hartmann F, Knitza J, Schett G, Kleyer A (2022)

Publication Type: Conference contribution, Abstract of a poster

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 629-629

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.3989

Authors with CRIS profile

Sara Bayat Lehrstuhl für Innere Medizin III Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology David Simon Department of Medicine 3 – Rheumatology and Immunology Johannes Knitza Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology

How to cite

APA:

Bayat, S., Tascilar, K., Bohr, D., Simon, D., Kronke, G., Hartmann, F.,... Kleyer, A. (2022, June). SIMILAR EFFICACY AND DRUG SURVIVAL RATES OF BARICITINIB MONOTHERAPY AND BARICITINIB/METHOTREXATE COMBINATION THERAPY IN REAL-LIFE TREATMENT OF RHEUMATOID ARTHRITIS - RESULTS FROM A PROSPECTIVE COHORT OF BARICITINIB-TREATED PATIENTS. Poster presentation.

MLA:

Bayat, Sara, et al. "SIMILAR EFFICACY AND DRUG SURVIVAL RATES OF BARICITINIB MONOTHERAPY AND BARICITINIB/METHOTREXATE COMBINATION THERAPY IN REAL-LIFE TREATMENT OF RHEUMATOID ARTHRITIS - RESULTS FROM A PROSPECTIVE COHORT OF BARICITINIB-TREATED PATIENTS." Presented at ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022.

BibTeX: Download